118 related articles for article (PubMed ID: 30701035)
1. Correction: MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment.
Yuan H; Wang X; Lu J; Zhang Q; Brandina I; Alexandrov I; Glazer RI
Oncotarget; 2018 Dec; 9(102):37808. PubMed ID: 30701035
[TBL] [Abstract][Full Text] [Related]
2. MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment.
Yuan H; Wang X; Lu J; Zhang Q; Brandina I; Alexandrov I; Glazer RI
Oncotarget; 2018 Jan; 9(8):8042-8053. PubMed ID: 29487713
[TBL] [Abstract][Full Text] [Related]
3. Correction: Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget.
Qiu YQ; Yang CW; Lee YZ; Yang RB; Lee CH; Hsu HY; Chang CC; Lee SJ
Oncotarget; 2019 Aug; 10(47):4919. PubMed ID: 31448057
[TBL] [Abstract][Full Text] [Related]
4. Correction: Inhibition of fibroblast secreted QSOX1 perturbs extracellular matrix in the tumor microenvironment and decreases tumor growth and metastasis in murine cancer models.
Feldman T; Grossman-Haham I; Elkis Y; Vilela P; Moskovits N; Barshack I; Salame TM; Fass D; Ilani T
Oncotarget; 2020 Oct; 11(40):3687. PubMed ID: 33088428
[TBL] [Abstract][Full Text] [Related]
5. Correction: A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment.
Ryan D; Sinha A; Bogan D; Davies J; Koziol J; ElShamy WM
Oncotarget; 2017 Dec; 8(68):113294. PubMed ID: 29350211
[TBL] [Abstract][Full Text] [Related]
6. Correction: A new bioluminescent reporter system to study the biodistribution of systematically injected tumor-derived bioluminescent extracellular vesicles in mice.
Gangadaran P; Li XJ; Lee HW; Oh JM; Kalimuthu S; Rajendran RL; Son SH; Baek SH; Singh TD; Zhu L; Jeong SY; Lee SW; Lee J; Ahn BC
Oncotarget; 2020 Mar; 11(11):1004-1005. PubMed ID: 32215188
[TBL] [Abstract][Full Text] [Related]
7. Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.
Reeves PM; Abbaslou MA; Kools FRW; Vutipongsatorn K; Tong X; Gavegnano C; Schinazi RF; Poznansky MC
Oncotarget; 2018 Jul; 9(54):30472. PubMed ID: 30101001
[TBL] [Abstract][Full Text] [Related]
8. Correction: MiR-451 as a new tumor marker for gastric cancer.
Shen Y; Gong JM; Zhou LL; Sheng JH
Oncotarget; 2019 Oct; 10(59):6396. PubMed ID: 31695848
[TBL] [Abstract][Full Text] [Related]
9. Correction: Se
Zhang HN; Feng WL; An CN; Li WG
Oncotarget; 2018 Nov; 9(92):36542. PubMed ID: 30559936
[TBL] [Abstract][Full Text] [Related]
10. Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.
Alon M; Arafeh R; Lee JS; Madan S; Kalaora S; Nagler A; Abgarian T; Greenberg P; Ruppin E; Samuels Y
Oncotarget; 2019 Feb; 10(13):1344. PubMed ID: 30863494
[TBL] [Abstract][Full Text] [Related]
11. Correction: Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma.
Valentini D; Rao M; Meng Q; von Landenberg A; Bartek J; Sinclair G; Paraschoudi G; Jäger E; Harvey-Peredo I; Dodoo E; Maeurer M
Oncotarget; 2018 Dec; 9(95):36817. PubMed ID: 30613370
[TBL] [Abstract][Full Text] [Related]
12. Correction: Sirt3-mediated mitophagy protects tumor cells against apoptosis under hypoxia.
Qiao A; Wang K; Yuan Y; Guan Y; Ren X; Li L; Chen X; Li F; Chen AF; Zhou J; Yang JM; Cheng Y
Oncotarget; 2018 Jun; 9(43):27318. PubMed ID: 29930768
[TBL] [Abstract][Full Text] [Related]
13. Correction: Metabolic pathway for the universal fluorescent recognition of tumor cells.
Fernandez-Carrascal A; Garcia-Algar M; Nazarenus M; Torres-Nuñez A; Guerrini L; Feliu N; Parak WJ; Garcia-Rico E; Alvarez-Puebla RA
Oncotarget; 2019 Nov; 10(61):6643. PubMed ID: 31762944
[TBL] [Abstract][Full Text] [Related]
14. Triggering CD40 on endothelial cells contributes to tumor growth.
Chiodoni C; Iezzi M; Guiducci C; Sangaletti S; Alessandrini I; Ratti C; Tiboni F; Musiani P; Granger DN; Colombo MP
J Exp Med; 2006 Oct; 203(11):2441-50. PubMed ID: 17043144
[TBL] [Abstract][Full Text] [Related]
15. Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor.
Hu Z; Hu Y; Liu X; Xi R; Zhang A; Liu D; Xie Q; Chen L
Oncotarget; 2018 Oct; 9(81):35283. PubMed ID: 30443295
[TBL] [Abstract][Full Text] [Related]
16. Correction: Immunogenicity of mammary tumor cells can be induced by shikonin via direct binding-interference with hnRNPA1.
Yin SY; Efferth T; Jian FY; Chen YH; Liu CI; Wang AHJ; Chen YR; Hsiao PW; Yang NS
Oncotarget; 2018 Aug; 9(63):32271. PubMed ID: 30181816
[TBL] [Abstract][Full Text] [Related]
17. Correction: Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting.
Kim JY; Han JH; Park G; Seo YW; Yun CW; Lee BC; Bae J; Moon AR; Kim TH
Oncotarget; 2018 Jun; 9(42):26977. PubMed ID: 29928495
[TBL] [Abstract][Full Text] [Related]
18. Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity
Shi F; Zhang J; Liu H; Wu L; Jiang H; Wu Q; Liu T; Lou M; Wu H
Oncotarget; 2018 Mar; 9(24):17255. PubMed ID: 29683149
[TBL] [Abstract][Full Text] [Related]
19. Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content.
Sandberg TP; Oosting J; van Pelt GW; Mesker WE; Tollenaar RAEM; Morreau H
Oncotarget; 2019 Mar; 10(24):2416. PubMed ID: 31040931
[TBL] [Abstract][Full Text] [Related]
20. Correction: Selenoprotein K deficiency inhibits melanoma by reducing calcium flux required for tumor growth and metastasis.
Marciel MP; Khadka VS; Deng Y; Kilicaslan P; Pham A; Bertino P; Lee K; Chen S; Glibetic N; Hoffmann FW; Matter ML; Hoffmann PR
Oncotarget; 2018 Jul; 9(56):30937. PubMed ID: 30112120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
